Evaluating only Recursion Pharmaceuticals’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Product failure.
Key Events Timeline
FOUNDING
FUNDING
CRISIS
SHUTDOWN
Full Analysis
Free · no account needed
Documented cause
Recursion built the most sophisticated AI platform for drug discovery, processing images of cellular phenotypes to identify drug candidates at scale. With $1.4B raised and a $5B peak valuation, it partnered with Roche and Bayer. But its AI-identified clinical candidates began failing Phase 2 trials. The gap between AI discovery speed and clinical validation timelines meant the company burned cash long before candidates could generate revenue. Deep cuts followed in 2024.
Lesson
“AI drug discovery companies must be capitalized for the full clinical validation cycle (10+ years) or partner out every candidate at Phase 1 — no AI can substitute for biology in Phase 2.”